Designing CD4 immunoadhesins for AIDS therapy - PubMed (original) (raw)

. 1989 Feb 9;337(6207):525-31.

doi: 10.1038/337525a0.

Affiliations

• PMID: 2536900
• DOI: 10.1038/337525a0

Designing CD4 immunoadhesins for AIDS therapy

D J Capon et al. Nature. 1989.

Abstract

A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.

PubMed Disclaimer

Similar articles

• Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
  Traunecker A, Schneider J, Kiefer H, Karjalainen K. Traunecker A, et al. Nature. 1989 May 4;339(6219):68-70. doi: 10.1038/339068a0. Nature. 1989. PMID: 2541344
• Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
  Traunecker A, Lüke W, Karjalainen K. Traunecker A, et al. Nature. 1988 Jan 7;331(6151):84-6. doi: 10.1038/331084a0. Nature. 1988. PMID: 2829024
• HIV infection is blocked in vitro by recombinant soluble CD4.
  Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD, Hirsch MS, Schooley RT, et al. Fisher RA, et al. Nature. 1988 Jan 7;331(6151):76-8. doi: 10.1038/331076a0. Nature. 1988. PMID: 2829022
• CD4 immunoadhesins in anti-HIV therapy: new developments.
  Chamow SM, Duliege AM, Ammann A, Kahn JO, Allen JD, Eichberg JW, Byrn RA, Capon DJ, Ward RH, Ashkenazi A. Chamow SM, et al. Int J Cancer Suppl. 1992;7:69-72. Int J Cancer Suppl. 1992. PMID: 1428410 Review.
• Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
  Farrar WL, Harel-Bellan A, Ferris DK. Farrar WL, et al. Crit Rev Immunol. 1988;8(4):315-39. Crit Rev Immunol. 1988. PMID: 2850890 Review.

Cited by

• Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.
  Zhang Z, Anang S, Nguyen HT, Fritschi C, Smith AB 3rd, Sodroski JG. Zhang Z, et al. iScience. 2024 May 28;27(7):110141. doi: 10.1016/j.isci.2024.110141. eCollection 2024 Jul 19. iScience. 2024. PMID: 38979012 Free PMC article.
• The dispensability of VH-VL pairing and the indispensability of VL domain integrity in the IgG1 secretion process.
  Choi J, Jeon Y, Roh Y, Jang J, Lee E, Villamante L, Kim M, Kwon MH. Choi J, et al. Front Mol Biosci. 2024 May 2;11:1346259. doi: 10.3389/fmolb.2024.1346259. eCollection 2024. Front Mol Biosci. 2024. PMID: 38756530 Free PMC article.
• N-Terminomic Identification of Intracellular MMP-2 Substrates in Cardiac Tissue.
  Hartley B, Bassiouni W, Roczkowsky A, Fahlman R, Schulz R, Julien O. Hartley B, et al. J Proteome Res. 2024 Oct 4;23(10):4188-4202. doi: 10.1021/acs.jproteome.3c00755. Epub 2024 Apr 22. J Proteome Res. 2024. PMID: 38647137
• Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.
  Wang Q, Zhang S, Nguyen HT, Sodroski J. Wang Q, et al. J Virol. 2024 Feb 20;98(2):e0159423. doi: 10.1128/jvi.01594-23. Epub 2024 Jan 30. J Virol. 2024. PMID: 38289101 Free PMC article.
• Next generation of multispecific antibody engineering.
  Keri D, Walker M, Singh I, Nishikawa K, Garces F. Keri D, et al. Antib Ther. 2023 Dec 8;7(1):37-52. doi: 10.1093/abt/tbad027. eCollection 2024 Jan. Antib Ther. 2023. PMID: 38235376 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program